Cited by 70Alzheimer's disease research and treatmentsRNA Research and SplicingDementia and Cognitive Impairment Research

Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer’s disease

Open access
McMillan, Pamela J., Strovas, Timothy J., Baum, Misa, Mitchell, Brooke K., Eck, Randall J., Hendricks, Nzinga, Wheeler, Jeanna M., Latimer, Caitlin S. +2 more·2021·Acta Neuropathologica Communications

Abstract

Several conserved nuclear RNA binding proteins (sut-1, sut-2, and parn-2) control tau aggregation and toxicity in C. elegans, mice, and human cells. MSUT2 protein normally resides in nuclear speckles, membraneless organelles composed of phase-separated RNAs and RNA-binding proteins that mediate critical steps in mRNA processing including mRNA splicing. We used human pathological tissue and transgenic mice to identify Alzheimer’s disease-specific cellular changes related to nuclear speckles. We observed that nuclear speckle constituent scaffold protein SRRM2 is mislocalized and accumulates in cytoplasmic lesions in AD brain tissue. Furthermore, progression of tauopathy in transgenic mice is accompanied by increasing mislocalization of SRRM2 from the neuronal nucleus to the soma. In AD brain tissue, SRRM2 mislocalization associates with increased severity of pathological tau deposition. These findings suggest potential mechanisms by which pathological tau impacts nuclear speckle function in diverse organisms ranging from C. elegans to mice to humans. Future translational studies aimed at restoring nuclear speckle homeostasis may provide novel candidate therapeutic targets for pharmacological intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-021-01219-1

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vitro studies using soluble phospho-tau oligomers find substantial alterations in nuclear-cytoplasmic transport.

    “Not only is there clear morphological evidence of nuclear alterations in AD, but also, in vitro studies using soluble phospho-tau oligomers as a perturbant find substantial alterations in nuclear–cytoplasmic transport (e.g., 31, 33, 37, 54).”

    From All the Tau We Cannot See (2023) · cites this paper as [37]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
McMillan, P. J., Strovas, T. J., Baum, M., Mitchell, B. K., Eck, R. J., Hendricks, N., Wheeler, J. M., Latimer, C. S., Keene, C. D., & Kraemer, B. C.
Affiliations
  • University of Washington (US)
  • VA Puget Sound Health Care System (US)
Corresponding author
Kraemer, Brian C.
Venue
Acta Neuropathologica Communications
Published
2021-06-29
Volume
9
Issue
1
Pages
117-117
ISSN
2051-5960 (ISSN-L)
OpenAlex
W3173689544
Cited by
64
References
53
Citations by year
2026: 9 · 2025: 12 · 2024: 14 · 2023: 14 · 2022: 14 · 2021: 1
FWCI
7.70
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Veterans Affairs
  • National Institute on Aging (RF1 AG055474, K08 AG065426, P30 AG0066509)
  • National Institute of Neurological Disorders and Stroke (R01NS064131)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
SRRM2, nuclear speckles, tau pathology, Alzheimer's disease, tauopathy, nuclear RNA-binding proteins, protein mislocalization, cytoplasmic accumulation, biomolecular condensates, mRNA splicing, transgenic mouse model, therapeutic target
MeSH terms
Nuclear Speckles, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Brain, Cytoplasm, Female, Humans, Male, Mice, Transgenic, Middle Aged, Neurons, RNA-Binding Proteins, tau Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review